Infervision vs Qure AI (2026)
Two non Western imaging AI companies that both built for scale before they built for the American market. Qure holds the broadest chest radiograph regulatory footprint in the market across nine products, with published device dossiers and deployments into screening programmes where radiologist capacity is thinnest. Infervision spans lung nodule detection and chest interpretation with United States operations alongside its origin market, which gives an American buyer a closer support relationship. Both illustrate the same pattern: regulatory dossiers are thorough because market access demands it, while commercial assurance documentation is thinner because it is handled in contract. Ask both for attestations and business associate terms directly rather than assuming.
- The regulatory footprint across chest radiography is the broadest in the market, spanning nine products with published device dossiers behind them.
- Deployments run where radiologist capacity is thinnest, including public health screening programmes, which is the hardest operating environment for imaging AI.
- On premise installation is supported and stated, which removes the data transfer question rather than governing it.
- Its suite spans lung nodule detection and chest interpretation with United States operations alongside its origin market.
- For a health system wanting chest coverage from a vendor with an established American presence, the support relationship is closer.
- Coverage extends across modalities rather than radiography alone.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Infervision and Qure AI are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Infervision | Qure AI |
|---|---|---|
| Primary category | Radiology & Imaging AI | Radiology & Imaging AI |
| Founded | 2015 | 2016 |
| Headquarters | Beijing, China | Mumbai, India |
| Website | global.infervision.com | qure.ai |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards Infervision its top capability grade on AI Centrality, FDA and Regulatory Status and Setting and Specialty Coverage. Set against Qure AI, Infervision grades higher on EHR and Interoperability Depth. Its thinnest published disclosure sits on Model Supply Chain Disclosure and AI Liability and Recourse. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
The AI Health Index awards Qure AI its top capability grade on several axes, including AI Centrality, Model and Technology Transparency and Clinical and Operational Evidence. Set against Infervision, Qure AI grades higher on several axes, including Model and Technology Transparency, Model Supply Chain Disclosure and Clinical and Operational Evidence. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
Questions buyers ask
Should we choose Infervision or Qure AI?
On the axes where the AI Health Index separates them, Infervision grades higher on EHR and Interoperability Depth, and Qure AI grades higher on several axes, including Model and Technology Transparency, Model Supply Chain Disclosure and Clinical and Operational Evidence. Qure AI leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.
Where do Infervision and Qure AI differ most?
The widest separation the AI Health Index records between Infervision and Qure AI is on Model and Technology Transparency, where Infervision grades C and Qure AI grades A. That axis sits in the AI Capability group, so it should carry the most weight for a buyer whose binding constraint is how much of the work the model itself is trusted to do.
Where do Infervision and Qure AI grade the same?
The AI Health Index grades Infervision and Qure AI the same on several axes, including AI Centrality, Autonomy and Oversight Model and AI Safety and PHI Stewardship. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
What have Infervision and Qure AI not disclosed?
At the last review, at least one of Infervision and Qure AI published thin or absent detail on Model Supply Chain Disclosure and AI Liability and Recourse. The AI Health Index treats an absent disclosure as a gap in the public record rather than a failure of the product, so these are the axes to get in writing during diligence instead of inferring from the grade.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
Both are non United States origin imaging vendors and the pattern this index records applies to both: regulatory effort follows market access while commercial assurance documentation is thinner, so a United States buyer should ask for attestations and business associate terms explicitly rather than assuming they exist. Do not compare on findings counts, which each vendor counts differently. Prevalence in your own population determines the false positive burden more than published sensitivity, and neither publishes performance stratified that way.